Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00611130 · ClinicalTrials.gov registry record · Phase 2
Vigabatrin for Treatment of Cocaine Dependence
A Phase 2 study of Cocaine Dependence, sponsored by Catalyst Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 186
- Enrollment target
- 11
- Study locations
NCT00611130: Completed Phase 2 study of Cocaine Dependence, sponsored by Catalyst Pharmaceuticals.
NCT00611130 is a Phase 2 study of Cocaine Dependence that has completed, run by Catalyst Pharmaceuticals. The registered enrollment target is 186 participants, below the 294-participant average among 38 other Cocaine Dependence trials with a reported enrollment target (37% lower). The trial reports 11 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00611130, a Phase 2 study of Cocaine Dependence, has completed, sponsored by Catalyst Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 186 participants
- Enrollment target
- 11
- Study locations
Study Summary
The objective of this study is to demonstrate that a larger proportion of vigabatrin-treated subjects than placebo-treated subjects will be cocaine-free in the last 2 weeks of treatment.
Primary Outcome
Number of subjects in the CPP-109 Vigabatrin Group vs. Number in Placebo Group abstinent from using cocaine during Weeks 11 and 12 of the Treatment Phase.
Conditions Studied
Interventions
- DRUG placebo
- DRUG vigabatrin
Study Locations (11)
California
- St. Luke's Hospital Addiction Pharmacology Research Laboratory - San Francisco
- Friends Research Institute - Torrance
Florida
- Operation PAR - Largo
- Segal Institute for Clinical Research - North Miami
Ohio
- Cincinnati Addiction Research Center (CinARC) - Cincinnati
- Dayton Veterans Affairs Medical Center - Dayton
Arkansas
- Addiction Treatment Clinic - Little Rock
Maryland
- Johns Hopkins Bayview Medical Center Center for Chemical Dependence - Baltimore
Massachusetts
- Boston University School of Medicine - Boston
New York
- New York University Mental Health and Addictive Disorders Research Program - New York
Texas
- University of Texas Health Science Center at San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2008-01 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
What the finished NCT00611130 record still lists
NCT00611130 is an interventional study that assigns participants to a tested intervention. The registered 186 participants enrollment target is mid-sized for trials with a published cap, below the 294-participant average among 38 other Cocaine Dependence trials with a reported enrollment target (37% lower).
The record links to 1 condition, with Cocaine Dependence appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00611130 lists 11 locations in 8 states (California, Florida, Ohio).
Frequently Asked Questions
What is clinical trial NCT00611130 about?
NCT00611130 is a clinical study titled "Vigabatrin for Treatment of Cocaine Dependence". The objective of this study is to demonstrate that a larger proportion of vigabatrin-treated subjects than placebo-treated subjects will be cocaine-free in the last 2 weeks of treatment.
What is the current status of trial NCT00611130?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 186 participants. The study started on 2008-01. Estimated completion is 2012-10.
What conditions does trial NCT00611130 study?
This clinical trial studies the following conditions: Cocaine Dependence.
What interventions are being tested in trial NCT00611130?
The interventions under investigation include: placebo (DRUG), vigabatrin (DRUG).
Who is sponsoring clinical trial NCT00611130?
This trial is sponsored by Catalyst Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00611130 being conducted?
This trial has 11 study locations across Arkansas, California, Florida, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cocaine Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00611130's enrollment target sits among peer trials
186 6th of 38 higher than 33 of 38 other Cocaine Dependence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cocaine Dependence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clavulanic Acid for the Treatment of Cocaine Use Disorder
ACTIVE NOT RECRUITING · Phase 2
-
Glutamatergic Modulation of Cocaine-related Deficits
COMPLETED · Phase 2
-
Disulfiram for Cocaine Abuse
COMPLETED · Phase 2
-
Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence
COMPLETED · Phase 2
-
Citalopram for Cocaine Dependence
COMPLETED · Phase 2
-
PHASE IIA: Trial of a Novel Ondansetron Formulation (OND-PR002) and Immediate-Release Methylphenidate (Ritalin®)(OND003IND)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03567889 · 186 participants · Phase 3
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
- NCT05281471 · 186 participants · Phase 3
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- NCT05405595 · 186 participants · Phase 1
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
- NCT05762107 · 186 participants · Phase 2
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia